Opening Asia for Russia

Mass vaccination against coronavirus with local drug QazVac begins in Kazakhstan

26.04.2021 36 просмотров

The first batch of 50,000 doses of the vaccine has arrived in the regions of the country.

The Ministry of Health of Kazakhstan from Monday starts mass vaccination of citizens with a local drug against coronavirus QazVac ("Kazvak"). doz-sobstvennoy-vaktsiny-qazvac/">The first batch of vaccine of 50,000 doses arrived in the regions of the republic.

As the Ministry of Health explained, the process of vaccinating citizens, which is now being conducted with the Sputnik V , Will not change. Kazakhstani vaccine will be available in vaccination rooms from April 26, and citizens will have the opportunity to choose the drug. At the same time, priority right to be vaccinated with QazVac will be given to people from risk groups - medical workers, teachers and law enforcement officers.

The Kazakhstani vaccine is recommended for people aged 18 years and older. It is administered intramuscularly. The course consists of two doses with an interval of 21 days.

Inactivated vaccine

Scientists and specialists of the Scientific Research Institute (NII) of Biological Safety Problems worked on the creation of QazVac. It was based on the experience of creating vaccines against other diseases, including highly pathogenic avian influenza and swine influenza. An inactivated vaccine is based on a virus that has been neutralized by exposure to chemicals. QazVac is included in the registry of the World Health Organization.

“The domestic technology uses a virus isolated in Kazakhstan in an inactivated form. Given that the virus is whole and killed, the vaccine has a fairly high degree of immunogenicity and safety,” explained the Research Institute for Biological Safety Problems. she was sent to the regions of the country. In May, it is planned to release the next batch of the drug from 50 thousand doses. Further, the production of the vaccine is planned to be gradually increased to 500-600 thousand doses per month.

It is planned that after the opening of a new biopharmaceutical plant in the village of Gvardeysky, Zhambyl region of Kazakhstan, the production of the QazVac vaccine will continue on its basis.

> As the President of Kazakhstan Kassym-Jomart Tokayev noted, the production of QazVac will be increased to make it available to all citizens.

Clinical trials

Now QazVac is in the third stage of clinical trials. On April 15, 50% of the third phase of clinical trials were completed, and the full study of the drug is planned to be completed in July. Minister of Health of Kazakhstan Alexey Tsoi said that according to preliminary data, the effectiveness of QazVac was more than 90%.

According to data obtained after two phases of clinical trials, when used correctly, the vaccine creates immunity all vaccinated participants. As part of the third stage of vaccine research, 3,000 volunteers were vaccinated in December 2020 and January this year. “Clinical studies of the third phase of the vaccine and the selection of volunteers were carried out according to the protocol approved by the Ministry of Health. According to the accepted rules, the volunteers were rewarded. After vaccination, there were no serious adverse events associated with vaccination among the participants, ”the Institute for Biological Safety Problems reported.

Vaccination campaign

In Kazakhstan, on February 1, people began to vaccinate the population against coronavirus with Sputnik V made in Russia. At the end of February, the shipment to the regions of the country of Sputnik V, produced on the basis of the Karaganda Pharmaceutical Complex (KPC), began. The volume of production of the CPK-based vaccine in April amounted to 1.5 million doses. In general, KFC, under an agreement with the Russian Direct Investment Fund, plans to produce 5 million doses of Sputnik V by September 2021.

The authorities of Kazakhstan plan to complete the vaccination of 10 million people from risk groups in September. Thus, in a country with a population of 18.8 million people, they expect to receive a cumulative effect of herd immunity.

As of April 25, 878,067 thousand people received the first component of the Sputnik V vaccine in the republic, the second component — 157,010.

In April, the situation with coronavirus in Kazakhstan remains difficult. According to the epidemic situation assessment matrix, during this month, most regions of the country were in a high-risk zone for the spread of coronavirus infection. The workload of infectious beds in hospitals is 42%, intensive care - 28%. More than 2,000 people infected with coronavirus are detected daily in the republic.

As of April 25, since the beginning of the epidemic, 306,400 cases of coronavirus infection have been registered in the country, 261,647 people have recovered, 3,550 have died. In relation to the population ( 18.8 million people) the proportion of infected people is 1.6%.

Новости партнёров